Abstract
Introduction Emerging evidence suggests that 20–30% of cases of cerebral palsy (CP) may have a genetic cause. Our group previously identified subsets of patients with CP or CP-masquerading conditions who warrant genetic testing, including those with regression or progressive neurological symptoms (CP masqueraders) and those without any known risk factors for CP (cryptogenic CP). Recognition of these subgroups in clinical settings remains challenging.
Methods To address this challenge, we developed and evaluated a computational phenotyping approach using ICD- 9/ICD-10 billing codes to automatically identify patients with unexplained CP or CP-masquerading conditions who may benefit from genetic testing. We applied this computational phenotyping approach to a cohort of 250 participants from the Boston Children’s Hospital CP Sequencing Study, aimed at identifying genetic causes in CP and CP-masquerading conditions.
Results Manual review served as the gold standard, identifying 8% as CP masqueraders, 42% as cryptogenic CP, and 50% as non-cryptogenic CP. Computational phenotyping based on ICD-9/10 codes achieved a sensitivity of 95%, specificity of 72%, positive predictive value of 77%, and negative predictive value of 94% in identifying cases warranting genetic testing.
Conclusions Our findings demonstrate the feasibility of using computational phenotyping to identify patients with CP or CP- masquerading conditions who warrant genetic testing. Further studies are needed to evaluate the effectiveness and real-world application of this tool in larger healthcare systems. Nonetheless, the computational phenotyping approach holds promise as a possible clinical decision support that could be integrated into electronic health record systems, enhancing clinical workflows and facilitating actionable genetic diagnoses.
Competing Interest Statement
SS has received grants from NIH/NINDS (K23NS119666); consulting fees from GLG, Guidepoint (which connected to a client, Fortress Biotech), Novartis, ExpertConnect, Orchard Therapeutics.
Funding Statement
SS has received grants from NIH/NINDS (K23NS119666).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We used data from participants enrolled in the Boston Children's Hospital (BCH) CP Sequencing Study, approved by the BCH Institutional Review Board, which performs next-generation sequencing on individuals with CP and CP masqueraders through the Children's Rare Disease Cohorts (CRDC) initiative.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data is available upon request to the corresponding author.
